FDA Approves Guselkumab as First IL-23 Inhibitor with Both SC and IV Induction Options for UC and CD
The FDA has approved a subcutaneous (SC) induction regimen of guselkumab (Tremfya) for adults with moderately to severely active ulcerative colitis (UC). This makes guselkumab the first and only IL-23 inhibitor to provide both SC and intravenous (IV) induction options for treating UC and Crohn’s disease, offering patients flexibility including self-administration from the start of […]